<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05020002</url>
  </required_header>
  <id_info>
    <org_study_id>2020P000018</org_study_id>
    <nct_id>NCT05020002</nct_id>
  </id_info>
  <brief_title>Extracellular RNA Biomarkers of Myotonic Dystrophy</brief_title>
  <official_title>Extracellular RNA Biomarkers of Myotonic Dystrophy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Beth Israel Deaconess Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Texas</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Current methods of measuring the response to new treatments for muscular dystrophies involve&#xD;
      the examination of small pieces of muscle tissue called biopsies. The investigators are&#xD;
      interested in finding less invasive methods that reduce the need for muscle biopsies. The&#xD;
      purpose of this research is to learn about the possibility of detecting and measuring the&#xD;
      activity and severity of muscular dystrophies by examining a urine sample and a blood sample.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 8, 2020</start_date>
  <completion_date type="Anticipated">December 2024</completion_date>
  <primary_completion_date type="Anticipated">December 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Extracellular RNA splice variants in biofluids</measure>
    <time_frame>4 years</time_frame>
    <description>The extracellular RNA biomarkers in the muscular dystrophy groups will be evaluated and compared with the extracellular RNA content in control groups. Statistical analysis will be used to evaluate the sensitivity and specificity of these markers as measurements of disease activity and severity.</description>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">215</enrollment>
  <condition>Myotonic Dystrophy</condition>
  <arm_group>
    <arm_group_label>Single biofluid collection</arm_group_label>
    <description>We will ask eligible volunteers to provide a single urine sample and undergo a single blood draw.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Serial biofluid and muscle function testing</arm_group_label>
    <description>We will ask eligible volunteers to provide a urine sample, a blood sample, and undergo standard muscle function tests once every six months over a two-year period, and undergo pulmonary function tests and electrocardiogram once per year for two years.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Biofluid and muscle tissue biopsy</arm_group_label>
    <description>We will ask eligible volunteers to provide a urine sample and undergo a muscle biopsy once.</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Urine; blood; serum; muscle tissue&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Males and females ages 5 years and older with myotonic dystrophy type 1 (DM1) or myotonic&#xD;
        dystrophy type 2 (DM2) confirmed by genetic testing or by clinical history and examination&#xD;
        are invited to participate. In addition, male and female healthy volunteers ages 18 and&#xD;
        older also are invited to participate.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects with DM1 or DM2 based on genetic testing and/or clinical criteria (some&#xD;
             subjects who have positive genetic testing may be asymptomatic, while other subjects&#xD;
             who show characteristic clinical features may have declined to have genetic testing&#xD;
             done). Control non-DM subjects are unknown to have DM or any other muscular dystrophy&#xD;
             by history and may have had no genetic testing.&#xD;
&#xD;
          -  Able to provide informed consent or assent for participation in the study.&#xD;
&#xD;
          -  Demographic characteristics for single biofluid collection: Males and females age 5&#xD;
             years and older (DM1, DM2, and non-DM).&#xD;
&#xD;
          -  Demographic characteristics for repeated measurements: Males and females age 14 years&#xD;
             and older with DM1.&#xD;
&#xD;
          -  Demographic characteristics for biofluid and muscle biopsy: Males and females, ages&#xD;
             18-65 years.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Medical history of any of the following. State of immunosuppression; coagulopathy;&#xD;
             pre-existing liver or kidney disease; documented HIV positive; documented hepatitis B&#xD;
             and/or C positive.&#xD;
&#xD;
          -  Medications and other drugs. Use of anti-platelet drugs within 7 days prior to blood&#xD;
             draw or biopsy; use of anticoagulants within 60 days prior to blood draw or biopsy;&#xD;
             active drug or alcohol use or dependence that, in the opinion of the biopsy surgeon,&#xD;
             would interfere with post-procedure wound care.&#xD;
&#xD;
          -  Other. Women that are pregnant, or intend to become pregnant, prior to the biopsy;&#xD;
             urine pregnancy test that is positive; inability or unwillingness of the subject to&#xD;
             give written informed consent.&#xD;
&#xD;
          -  Other. Inability or unwillingness of the subject to give written informed consent or&#xD;
             assent.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thurman M. Wheeler, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Parker Conquest</last_name>
    <phone>617-726-7506</phone>
    <email>econquest@mgh.harvard.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Brigham McKee</last_name>
    <phone>617-726-7506</phone>
    <email>bmckee2@mgh.harvard.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Louis Beers</last_name>
      <email>lbeers@bwh.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Anthony Amato, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02129</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Parker Conquest</last_name>
      <phone>617-726-7506</phone>
      <email>econquest@mgh.harvard.edu</email>
    </contact>
    <contact_backup>
      <last_name>Brigham McKee</last_name>
      <phone>617-726-7506</phone>
      <email>bmckee2@mgh.harvard.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Thurman M. Wheeler, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Soleil Samaan</last_name>
      <email>ssamaan@bidmc.harvard.edu</email>
    </contact>
    <contact_backup>
      <last_name>Hilda Gutierrez, MD</last_name>
      <email>hgutier1@bidmc.harvard.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Seward B. Rutkove, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Courtney E. McIlduff, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Texas Southwestern</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karla Castro</last_name>
      <phone>214-456-3696</phone>
      <email>karla.castroochoa@utsouthwestern.edu</email>
    </contact>
    <investigator>
      <last_name>Susan T. Iannaccone, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Antoury L, Hu N, Balaj L, Das S, Georghiou S, Darras B, Clark T, Breakefield XO, Wheeler TM. Analysis of extracellular mRNA in human urine reveals splice variant biomarkers of muscular dystrophies. Nat Commun. 2018 Sep 25;9(1):3906. doi: 10.1038/s41467-018-06206-0.</citation>
    <PMID>30254196</PMID>
  </reference>
  <reference>
    <citation>Antoury L, Hu N, Darras B, Wheeler TM. Urine mRNA to identify a novel pseudoexon causing dystrophinopathy. Ann Clin Transl Neurol. 2019 May 17;6(6):1106-1112. doi: 10.1002/acn3.777. eCollection 2019 Jun.</citation>
    <PMID>31211175</PMID>
  </reference>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 16, 2021</study_first_submitted>
  <study_first_submitted_qc>August 20, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 25, 2021</study_first_posted>
  <last_update_submitted>August 20, 2021</last_update_submitted>
  <last_update_submitted_qc>August 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Thurman Wheeler, M.D</investigator_full_name>
    <investigator_title>Physician Scientist</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myotonic Dystrophy</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

